Novel biologic and molecular targets in COPD: Bridging precision medicine and lung regeneration

Samir Mohamed Mahmoud Fahyim; Hesham Atef AbdelHalim

doi:10.2478/pneum-2026-0005

.blurhash-client-img { display: none !important; }

Novel biologic and molecular targets in COPD: Bridging precision medicine and lung regeneration

Pneumologia

Volume 75 (2026): Issue 1 (January 2026)

By: Samir Mohamed Mahmoud Fahyim and Hesham Atef AbdelHalim

Open Access

|Apr 2026

Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, et al. Treatable traits: toward precision medicine of chronic airway diseases. European Respiratory Journal. 2016;47: 410–419. doi:10.1183/13993003.01359-2015
Open DOI Search in Google Scholar Back to article
Yadav AK, Gu W, Zhang T, Xu X, Yu L. Current perspectives on biological therapy for COPD. COPD Journal of Chronic Obstructive Pulmonary Disease. 2023;20: 197–209. doi:10.1080/15412555.2023.2187210
Open DOI Search in Google Scholar Back to article
Singh D, Lobo AM, Higham A, Navarrete BA. Biological therapy in COPD management: current evidence, challenges and opportunities. Archivos de Bronconeumologia. 2025;61: 690–696. doi:10.1016/J.ARBRES.2025.07.017
Open DOI Search in Google Scholar Back to article
Milad N, Pineault M, Tremblay F, Routhier J, Lechasseur A, Beaulieu MJ, et al. Smoking status impacts treatment efficacy in smoke-induced lung inflammation: A pre-clinical study. Frontiers in Pharmacology. 2022;13: 971238. doi:10.3389/FPHAR.2022.971238/BIBTEX
Open DOI Search in Google Scholar Back to article
Kortekaas RK, Geillinger-Kästle KE, Fuentes-Mateos R, van Orsoy R, Al-Alyan N, Burgess JK, et al. The disruptive effects of COPD exacerbation-associated factors on epithelial repair responses. Frontiers in Immunology. 2024;15: 1346491. doi:10.3389/FIMMU.2024.1346491/BIBTEX
Open DOI Search in Google Scholar Back to article
Fahyim SMM, AbdelHalim HA, Hassan ESSM. Association between serum interleukin-6 concentrations, chronic obstructive pulmonary disease, and its relation to severity, acute exacerbation, and its effect on pulmonary function test. The Egyptian Journal of Bronchology. 2025;19: 1–7. doi:10.1186/S43168-025-00388-0
Open DOI Search in Google Scholar Back to article
Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. New England Journal of Medicine. 2018;378: 1671–1680. doi:10.1056/NEJMOA1713901
Open DOI Search in Google Scholar Back to article
Văruț RM, Dalia D, Radivojevic K, Trasca DM, Stoica G-A, Adrian NS, et al. Targeted biologic therapies in severe asthma: mechanisms, biomarkers, and clinical applications. Pharmaceuticals. 2025;18: 1021. doi:10.3390/ph18071021
Open DOI Search in Google Scholar Back to article
Bhatt SP, Agusti A, Bafadhel M, Christenson SA, Bon J, Donaldson GC, et al. Phenotypes, etiotypes, and endotypes of exacerbations of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine. 2023;208: 1026–1041. doi:10.1164/RCCM.202209-1748SO
Open DOI Search in Google Scholar Back to article
Fahyim SMM, AbdelHalim HA, Hassan ESSM. Blood eosinophil variability in patients presenting with acute exacerbations of COPD within the past year and its correlation with treatment plan. Egyptian Journal of Bronchology. 2024;18: 1–5. doi:10.1186/S43168-024-00274-1
Open DOI Search in Google Scholar Back to article
Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nature Reviews Immunology. 2012;13: 9–22. doi:10.1038/nri3341
Open DOI Search in Google Scholar Back to article
van der Schans S, Goossens LMA, Boland MRS, Kocks JWH, Postma MJ, van Boven JFM, et al. Systematic review and quality appraisal of cost-effectiveness analyses of pharmacologic maintenance treatment for chronic obstructive pulmonary disease: methodological considerations and recommendations. PharmacoEconomics. 2016;35: 43–63. doi:10.1007/S40273-016-0448-2
Open DOI Search in Google Scholar Back to article
Katsoulis O, Toussaint M, Jackson MM, Mallia P, Footitt J, Mincham KT, et al. Neutrophil extracellular traps promote immunopathogenesis of virus-induced COPD exacerbations. Nature Communications. 2024;15: 1–14. doi:10.1038/s41467-024-50197-0
Open DOI Search in Google Scholar Back to article
Lazaar AL, Miller BE, Donald AC, Keeley T, Ambery C, Russell J, et al. CXCR2 antagonist for patients with chronic obstructive pulmonary disease with chronic mucus hypersecretion: A phase 2b trial. Respiratory Research. 2020;21: 1–10. doi:10.1186/S12931-020-01401-4/TABLES/5
Open DOI Search in Google Scholar Back to article
Zhu Z, Gong D, Chen Y, Yuan M, Qian H, He B, et al. A review of research advances in the modulation of olfactory receptors for COPD inflammation and airway remodeling. Frontiers in Immunology. 2025;16: 1612165. doi:10.3389/FIMMU.2025.1612165/FULL
Open DOI Search in Google Scholar Back to article
Le Floc’h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ra antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75: 1188. doi:10.1111/ALL.14151
Open DOI Search in Google Scholar Back to article
Tsioumpekou M, Krijgsman D, Leusen JHWW, Olofsen PA. The role of cytokines in neutrophil development, tissue homing, function and plasticity in health and disease. Cells. 2023;12: 1981. doi:10.3390/CELLS12151981
Open DOI Search in Google Scholar Back to article
Bakakos A, Sotiropoulou Z, Anagnostopoulos N, Vontetsianos A, Cholidou K, Papaioannou AI, et al. Anti-inflammatory agents for the management of COPD - Quo Vadis? Respiratory Medicine. 2025;248: 108396. doi:10.1016/J.RMED.2025.108396
Open DOI Search in Google Scholar Back to article
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier C, Bafadhel M, Christenson S, et al. Dupilumab reduces exacerbations and improves lung function and quality of life in patients with chronic obstructive pulmonary disease and type 2 inflammation: the NOTUS trial. Chest. 2024;166: A4821–5. doi:10.1016/j.chest.2024.06.2868
Open DOI Search in Google Scholar Back to article
Kychygina A, Cassagne M, Tauber M, Galiacy S, Paul C, Fournié P, et al. Dupilumab-associated adverse events during treatment of allergic diseases. Clinical Reviews in Allergy & Immunology. 2022;62: 519–533. doi:10.1007/s12016-022-08934-0
Open DOI Search in Google Scholar Back to article
Ameer OZ, Mansour GK, Al-Amoudi RS, Abu-Owaimer FM. Exploring dupilumab for asthma: from mechanistic insights to clinical outcomes, safety, and cost-effectiveness. Frontiers in Pharmacology. 2025;16: 1631321. doi:10.3389/FPHAR.2025.1631321/BIBTEX
Open DOI Search in Google Scholar Back to article
Matucci A, Maggi E, Vultaggio A. Eosinophils, the IL-5/IL-5Ra axis, and the biologic effects of benralizumab in severe asthma. Respiratory Medicine. 2019;160: 105819. doi:10.1016/J.RMED.2019.105819
Open DOI Search in Google Scholar Back to article
Criner GJ, Celli BR, Singh D, Agusti A, Papi A, Jison M, et al. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. The Lancet Respiratory Medicine. 2020;8: 158–170. doi:10.1016/S2213-2600(19)30338-8
Open DOI Search in Google Scholar Back to article
Desaintjean C, Ahmad K, Traclet J, Gerfaud-Valentin M, Durel CA, Glerant JC, et al. Mepolizumab and benralizumab in patients with severe asthma and a history of eosinophilic granulomatosis with polyangiitis. Frontiers in Medicine. 2024;11: 1341310. doi:10.3389/fmed.2024.1341310
Open DOI Search in Google Scholar Back to article
Sciurba FC, Criner GJ, Christenson SA, Martinez FJ, Papi A, Roche N, et al. Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype. New England Journal of Medicine. 2025;392: 1710–1720.PAGEGROUP:STRING:PUBLICATION. doi:10.1056/NEJMOA2413181
Open DOI Search in Google Scholar Back to article
Pavord ID, Chapman KR, Bafadhel M, Sciurba FC, Bradford ES, Harris SS, et al. Mepolizumab for eosinophil-associated COPD: Analysis of metrex and metreo. International Journal of Chronic Obstructive Pulmonary Disease. 2021;16: 1755–1770. doi:10.2147/COPD.S294333
Open DOI Search in Google Scholar Back to article
Hitt EM, Powell AJ. Ensifentrine: a novel option for maintenance of chronic obstructive pulmonary disease. The Journal of Pharmacy Technology: Jpt: Official Publication of the Association of Pharmacy Technicians. 2025;41: 242–248. doi:10.1177/87551225251350899
Open DOI Search in Google Scholar Back to article
Appleton LK, Hanania NA, Adrish M. Personalized COPD care: the future of precision-based therapies. Journal of Clinical Medicine. 2024;13: 6339. doi:10.3390/jcm13216339
Open DOI Search in Google Scholar Back to article
Donohue JF, Rheault T, MacDonald-Berko M, Bengtsson T, Rickard K. Ensifentrine as a novel, inhaled treatment for patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease. 2023;18: 1611–1622. doi:10.2147/COPD.S413436
Open DOI Search in Google Scholar Back to article
Kirsten AM, Förster K, Radeczky E, Linnhoff A, Balint B, Watz H, et al. The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD. Pulmonary Pharmacology & Therapeutics. 2015;31: 36–41. doi:10.1016/J.PUPT.2015.02.001
Open DOI Search in Google Scholar Back to article
Zhang X, Guo R, Kambara H, Ma F, Luo H. The role of CXCR2 in acute inflammatory responses and its antagonists as anti-inflammatory therapeutics. Current Opinion in Hematology. 2019;26: 28–33. doi:10.1097/MOH.0000000000000476
Open DOI Search in Google Scholar Back to article
Ahmadi A, Ahrari S, Salimian J, Salehi Z, Karimi M, Emamvirdizadeh A, et al. p38 MAPK signaling in chronic obstructive pulmonary disease pathogenesis and inhibitor therapeutics. Cell Commun Signal. 2023;21: 1–26. doi:10.1186/S12964-023-01337-4
Open DOI Search in Google Scholar Back to article
Raza A, Crothers JW, McGill MM, Mawe GM, Teuscher C, Krementsov DN. Anti-inflammatory roles of p38a MAPK in macrophages are context dependent and require IL-10. Journal of Leukocyte Biology. 2017;102: 1219–1227. doi:10.1189/JLB.2AB0116-009RR
Open DOI Search in Google Scholar Back to article
Loboda A, Damulewicz M, Pyza E, Jozkowicz A, Dulak J. Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism. Cellular and Molecular Life Sciences. 2016;73: 3221–3247. doi:10.1007/S00018-016-2223-0
Open DOI Search in Google Scholar Back to article
Cazzola M, Page C, Rogliani P, Calzetta L, Matera MG. PI3K inhibitors as potential therapeutic agents for the treatment of COPD with associated atherosclerosis. Drugs. 2025;85: 741–753. doi:10.1007/S40265-025-02179-9
Open DOI Search in Google Scholar Back to article
Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Cole J, Bafadhel M, et al. Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts. New England Journal of Medicine. 2023;389: 205–214. PAGEGROUP: STRING:PUBLICATION. doi:10.1056/NEJMOA2303951
Open DOI Search in Google Scholar Back to article
Phillips KM, Lavere PF, Hanania NA, Adrish M. The emerging biomarkers in chronic obstructive pulmonary disease: a narrative review. Diagnostics (Basel). 2025;15: 1245. doi:10.3390/DIAGNOSTICS15101245
Open DOI Search in Google Scholar Back to article
de Boer WI, Yao HRI. Full article: future therapeutic treatment of COPD: struggle between oxidants and cytokines. International Journal of Chronic Obstructive Pulmonary Disease. 2007;2: 205–228. doi: 10.2147/copd.s12159956
Open DOI Search in Google Scholar Back to article

Authors

Metrics

Articles in this issue

DOI: https://doi.org/10.2478/pneum-2026-0005 | Journal eISSN: 2247-059X | Journal ISSN: 2067-2993

Journal RSS Feed

Language: English

Page range: 29 - 38

Published on: Apr 15, 2026

Published by: Romanian Society of Pneumology

In partnership with: Paradigm Publishing Services

Publication frequency: Volume open

Keywords:

COPD,

Related subjects:

Clinical medicine, other,

Internal medicine,

Pneumology

© 2026 Samir Mohamed Mahmoud Fahyim, Hesham Atef AbdelHalim, published by Romanian Society of Pneumology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Volume 75 (2026): Issue 1 (January 2026)